Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04870021
Other study ID # F.No.3-107/2013-IERC/HSA
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date March 15, 2015
Est. completion date June 30, 2016

Study information

Verified date April 2021
Source Quaid-e-Azam University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

With 2.5% prevalence in general population, Pakistan is an intermediate endemicity country for hepatitis B. However, wide disparity exists across the country as disease prevalence in general population soars as high as 14% in hyper endemic areas. This hyper endemicity increases the risk of acquiring infection via vertical and horizontal routes of disease transmission. National immunization schedule in Pakistan administers the first vaccine against hepatitis B at 6th week after infant birth. Owing to this 6 week interlude the existing immunization schedule may not provide adequate protection to a newborn against the disease. A monovalent hepatitis B vaccination shot, administered within 12 hours of birth, is the preferred strategy for disease control in hyper endemic areas. The National Immunization Technical Advisory Groups around the world are expected to use rigorous scientific evidence and make changes in the immunization schedule and vaccine dosage, responding to the evolving epidemiology of childhood diseases. Such research on local evidence for hepatitis B vaccine in Pakistan is not available and our research fills this gap by This research studied the hepatitis B vaccine response, in two cohorts of healthy infants. An open labeled, randomized controlled, non-inferiority, vaccine trial methodology was used. Margin of non non-inferiority (Δ) was set at 5%. The trial administered hepatitis B birth dose as an intervention and vaccination done under the national immunization schedule was taken as standard of care.


Description:

Study Design: The study is an unblinded, open-labeled, non-inferiority, randomized controlled trial with a participant ratio of 1:1 in each group (the design remained the same through the length of the study and no changes were made to the methods approved in the protocol). The reason for making the study as an open labeled trial is that mothers could not feasibly be blinded from the information on allocation scheme, and the information on vaccine given to infants could not be held back from family and parents. Another non-inferiority vaccine trial in Pakistan also used a similar approach in allocation scheme Trial Profile The trial was done at a tertiary care hospital in an urban area from March 15, 2015, to May 20, 2016. Assuming an attrition rate of 25%, the study enrolled 296 expectant mothers for allocation in two groups, intervention, and control group. Participants of the trial: The study population was healthy newborns born to healthy females, in a health facility. These pregnant women were registered for institutional deliveries at Countess Dufferin Fund (CDF) Hospital, Hyderabad. The CDF Hospital Hyderabad is a tertiary care hospital for women and children. The hospital is located in a populous downtown area of the Hyderabad city and caters to patients coming from the urban areas of the city. The average daily out-patient visits to the hospital are 200 women. The average number of daily deliveries in the hospital is 25. All women who attended an antenatal clinic for a routine examination by gynecologist were evaluated on following inclusion criteria; 1. Full term pregnant and registered for delivery at CDF Hospital Hyderabad 2.1. An absence of a chronic illness (Diabetes / Tuberculosis / Hypertension) 3.1. No serological marker (HBs Ag) of prior exposure to hepatitis B Inclusion criteria for mothers and Recruitment process All women who attended an antenatal clinic for a routine examination by gynecologist were evaluated on following inclusion criteria; 1. Full term pregnant and registered for delivery at CDF Hospital Hyderabad 2. An absence of a chronic illness (Diabetes / Tuberculosis / Hypertension) 3. No serological marker (HBs Ag) of prior exposure to hepatitis B Prior to the due date for childbirth, while attending the antenatal clinic, these females were approached and informed about the study. Those who were willing to participate were given a consent form to sign. After the informed consent, blood was obtained by a finger prick and a drop of blood was put onto the Abbot's Determine ® rapid testing kit for detection of hepatitis B surface antigen. The Determine ® has sensitivity, (negative predictive value) of 98% and specificity, (positive predictive value) of 100%, compared to the Enzyme Link Immunosorbent Assay (96). The results were interpreted as follows; - Two red bars meant blood is positive for hepatitis B surface antigen - Single red bar meant blood is negative for hepatitis B surface antigen Women who were negative for hepatitis B surface antigen were then allocated into an intervention or a control group (details of the methodology are given below). They were followed until they delivered and were discharged from the hospital with a healthy baby. For vaccine given at birth, other researchers have also enrolled infants as subjects of the vaccine trials(97)(98)(99). Infants have also been selected as trial participants and the hepatitis B vaccine was given to infants in trials of preventing mother to child transmission of hepatitis B(100). Exclusion criteria for neonates: After the delivery infants born in both groups were examined by a trained midwife for following criteria; 1. Weight, less than 2000 grams 2. Signs and Symptoms of febrile Illness/sepsis 3. Congenital Malformation 4. Signs of Cyanosis 5. Difficulty in breathing The newborns who fulfilled the inclusion criteria, i.e., weight more than 2000 grams and absence of above-mentioned criteria were followed up. Intervention One cc of intravenous blood was drawn from the peripheral veins of these healthy newborn. The blood was immediately centrifuged, and serum was put in a plastic container, labeled with a unique identification number. The serum containers were frozen and then sent using a cold chain container, to Pakistan Medical Research Council laboratory at Jinnah Postgraduate Medical Center Karachi. The serum was tested for anti-hepatitis B surface antigen antibody on Enzyme Immunoassay (EIA) kit DS-EIA-Anti-HBsAg, manufactured by DSI S.r.I (Italy). After obtaining a blood sample, infants born to mothers in the intervention group were administered GSK's ® recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs. This birth dose of hepatitis B was followed by zero dose oral polio vaccine as per hospital policy. Infants born to mother in the control group were given oral polio vaccine as per the hospital policy. Subsequent vaccinations in both groups of infants were administered as per the expanded program on immunization schedule in Pakistan. After discharge from the hospital, both groups of children were followed until the completion of the third dose of Diptheria - Pertussis Tetanus - Hemophilus Influenza Type B - Hepatitis B - Pneumococcal (DPT-HiB-HBV-PCV) vaccine offered under the Expanded Program on Immunization. The follow up was done with caregivers at 6, 10 and 14 weeks, follow up started at 8 weeks and duration of follow-up was up to 10 weeks after the 3rd shot of DPT-HiB-HBV-PCV vaccine. After the discharge of mothers from hospital, preformed, short text messages (SMS) were sent to parents, reminding them of the due date for as per the vaccination schedule. One day after the due date of the vaccine shot, a phone call was made to confirm the child was vaccinated or not. The parents were approached after eight weeks of the last DPT-HiB-HBV-PCV vaccine shot. They were requested to bring the child to the hospital for a follow-up blood test to evaluate the presence of anti-HBs Ag-Ab titer in the blood. Upon the follow-up visit, infants were weighed, and 1 cc venous blood was drawn from the peripheral veins. Blood was centrifuged, and serum was stored in a plastic container labeled with a unique number. All the samples were then sent in cold chain to Pakistan Medical Research Council laboratory at the Jinnah Postgraduate Medical Center Karachi. Intervention Group: Four (4) mothers from the intervention group were shifted to a teaching hospital, prior to delivering a baby. Baseline blood samples were taken from 144 babies and the birth dose was administered. During subsequent follow-up, cell numbers of three mothers were not responsive, after a period of three months, they were declared as lost to follow-up. Baseline antibody titer in serum of fourteen infants was found to be greater than10 mIU/ml. These children were not followed. One child died, and parents of five children refused to continue and did not allow obtaining a peripheral follow up blood sample. Control Group: A high attrition of study participants happened in the control group. Thirty-two expectant mothers refused to participate in the study when told that their babies would not get birth dose hepatitis B vaccination. This attrition occurred despite an explanation of trial to the control group participants, prior to the enrollment. The phenomenon of high attrition in the control group is a well-known and well-documented effect of an unblinded trial. Margin of non-inferiority In a non-inferiority trial, if the upper limit of 95% confidence interval is less than the margin of non-inferiority i.e. delta (Δ), there is evidence of non-inferiority cases(48). At the protocol development stage, published literature was reviewed for seroprotection correlates. For the purpose of this trial, we calculated the Δ as the difference in seroprotection correlates with or without the birth dose of hepatitis B vaccine, and the Δ for this study was set to be 5%. The trial outcome set at the time of protocol design was not changed during the course of study. Sample Size In the non-inferiority trials, where the primary response variable is dichotomous, it is assumed that the event rate for the two interventions is equal to p i.e. p = p intervention = p control. With this assumption the formula becomes as under(48); 2N = 4p (1-p) (Zα - Zβ)2 / Δ2 A brief explanation of the variables used in the equation is given below P = 0.957 (proportion of children attaining seroprotection correlates) (104) Δ = 0.05 (5%) Zα = 2.57 (99% CI) Zβ = 0.89 (80% power) After solving the equation 2 N comes out to be 228, hence 1 N =114. Thus, to get the answer to questions posed in the study; the number of subjects in one arm of the trial is 114. The trial was planned to end after the last follow up


Recruitment information / eligibility

Status Completed
Enrollment 218
Est. completion date June 30, 2016
Est. primary completion date November 30, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 8 Months
Eligibility Inclusion Criteria: - Newborn with weight more than 2000 grams - Born to health mothers - No sign of congenital disease Exclusion Criteria: - Low birth weight newborn - Signs and Symptoms of febrile Illness/sepsis - Congenital Malformation - Signs of Cyanosis - Difficulty in breathing

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm),
recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs
Behavioral:
Short text messages and calls to parents for compliance to routine immunization schedule
After the discharge of mothers from hospital, preformed, short text messages (SMS) were sent to parents, reminding them of the due date for as per the vaccination schedule. One day after the due date of the vaccine shot, a phone call was made to confirm the child was vaccinated or not

Locations

Country Name City State
Pakistan Countess Dufferin Fund (CDF) Hospital Hyderabad

Sponsors (3)

Lead Sponsor Collaborator
Quaid-e-Azam University Health Services Academy, Islamabad, Pakistan, Medical Research Council, Pakistan

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sero-proetction Level The outcome of the study is the measurement of seroprotection correlates against hepatitis B, i.e., anti-hepatitis B surface antigen antibody titer 8 weeks after third pentavalent vaccination
Secondary Adverse event The secondary response variable in this trial is any adverse event reported after vaccination. 96 hours after the administration of hepatitis B birth dose
See also
  Status Clinical Trial Phase
Completed NCT01182311 - Duration of Long-term Immunity After Hepatitis B Virus Immunization
Completed NCT04971928 - Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment Phase 1
Completed NCT03285620 - A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants Phase 1
Completed NCT01884415 - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis Phase 3
Recruiting NCT05404919 - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates Phase 2
Completed NCT02153320 - Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers Phase 1
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Completed NCT03567382 - Arresting Vertical Transmission of Hepatitis B Virus Phase 4
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Not yet recruiting NCT03604016 - Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Terminated NCT02604199 - A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection Phase 2
Completed NCT02540538 - Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders Phase 1
Completed NCT02421666 - A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV N/A
Completed NCT02169674 - Hepatitis B Booster Study in Adolescence Phase 4
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01732354 - Study for Consolidation Period of Chronic Hepatitis B
Completed NCT01368497 - Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection Phase 3
Recruiting NCT01462981 - Cohort of Hepatitis B Research of Amsterdam N/A